The use of transdermal opioids in patients with malignant pain requires an individualised and aggressive approach

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.21, Iss.10, 2005-10, pp. : 24-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Practice Guidelines for Transdermal Opioids in Malignant Pain

By Tracy L. Skaer

Drugs, Vol. 64, Iss. 23, 2004-01 ,pp. : 2629-2638

Adis International

Access to resources Recommend Favorite

Use of Transdermal Fentanyl in Patients with Continuous Non-Malignant Pain: A Case Report Series

By Libretto S.E.

Clinical Drug Investigation, Vol. 22, Iss. 7, 2002-07 ,pp. : 473-483

Adis International

Access to resources Recommend Favorite

Buprenorphine 5, 10 and 20 μg/h Transdermal Patch: A Guide to Its Use in Chronic Non-Malignant Pain

By Plosker Greg L. Lyseng-Williamson Katherine A.

CNS Drugs, Vol. 26, Iss. 4, 2012-04 ,pp. : 367-373

Adis International

Access to resources Recommend Favorite

Buprenorphine 5, 10 and 20 μg/h Transdermal Patch: A Review of its Use in the Management of Chronic Non-Malignant Pain

By Plosker Greg L.

Drugs, Vol. 71, Iss. 18, 2011-12 ,pp. : 2491-2509

Adis International

Access to resources Recommend Favorite

Non-Analgesic Effects of Opioids: The Cognitive Effects of Opioids in Chronic Pain of Malignant and Non-Malignant Origin. An Update.

Current Pharmaceutical Design, Vol. 18, Iss. 37, 2012-12 ,pp. : 6116-6122

Bentham Science Publishers

Access to resources Recommend Favorite